Maruho Broadens Derma Horizons Through Dual Licensing Deals

Derma specialist Maruho has taken steps to recharge its pipeline through deals with fellow Japanese firms for two novel assets.

Earth

Mid-sized dermatology specialist Maruho Co. Ltd. has licensed in selected rights in Japan to a novel antibody from Chugai Pharmaceutical Co. Ltd.and in global markets to a Janus kinase (JAK) inhibitor developed by Astellas Pharma Inc.

In licensing to Maruho the Japanese rights to develop and market nemolizumab (CIM331) for skin disorders, Chugai has taken a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category